HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Bio-Rad Laboratories, Inc. BIO announced that the performance of its QX200 Droplet Digital polymerase chain reaction (PCR) (ddPCR) System for the clinical detection of SARS-CoV-2 was proved to be more ...
Bio-Rad Laboratories, announced the launch of the QX700 System-compatible Vericheck ddPCR Kit portfolio for critical quality control (QC) workflows in advanced cell and gene therapy development and ...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today announced the launch of the QX700 System-compatible Vericheck ddPCR Kit portfolio for ...
Hercules, CA -- October 19, 2015 -- Bio-Rad's Droplet Digital PCR (ddPCR™) technology identifies viral RNA mutations in clinical samples with greater precision, sensitivity, and reproducibility than ...
Earnings Call Insights: Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Norman Schwartz, Chairman & CEO, indicated Bio-Rad delivered solid execution in Q2 2025, with both revenue and operating margin ...
Bio-Rad Laboratories, Inc. announced the launch of five Droplet Digital™ PCR (ddPCR) Multiplex Mutation Screening Kits for detecting several key actionable cancer mutations and the wild-type allele in ...
Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results